Allogeneic Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Allogeneic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Phase 4

Improving White Blood Cell Collection From Healthy Donors

Allogeneic Granulocyte Donation
National Institutes of Health Clinical Center (CC)1,000 enrolled1 locationNCT01553214
Recruiting
Not Applicable

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic DisordersPatients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
The General Hospital of Western Theater Command45 enrolled1 locationNCT07483385
Recruiting

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
National Heart, Lung, and Blood Institute (NHLBI)40 enrolled1 locationNCT06093867
Recruiting
Phase 2

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Allogeneic Stem Cell Transplant Recipient
Hackensack Meridian Health209 enrolled3 locationsNCT07214688
Recruiting
Phase 4

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Chinese PLA General Hospital200 enrolled1 locationNCT07101588
Recruiting
Phase 3

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 3

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

VenentoclaxALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONMyeloid Malignancies+3 more
First Affiliated Hospital of Zhejiang University186 enrolled18 locationsNCT07396480
Recruiting
Phase 3

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplant
Shanghai Jiao Tong University School of Medicine316 enrolled1 locationNCT06705062
Recruiting
Phase 2

Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant

Allogeneic Stell Cell TransplantViral Infection
Children's Hospital Medical Center, Cincinnati180 enrolled1 locationNCT04230356
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Early Phase 1

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Case Comprehensive Cancer Center20 enrolled1 locationNCT04332341
Recruiting
Not Applicable

Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Rigshospitalet, Denmark110 enrolled1 locationNCT07341698
Recruiting

Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation

Allogeneic Transplantation
M.D. Anderson Cancer Center1,200 enrolled1 locationNCT06450353
Recruiting
Phase 1Phase 2

A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

Acute Leukemia, High RiskMyelodysplastic Syndromes, High RiskHematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
Ciusss de L'Est de l'Île de Montréal7 enrolled1 locationNCT07301866
Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University60 enrolled1 locationNCT05088356
Recruiting
Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

AML (Acute Myeloid Leukemia)Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, China134 enrolled5 locationsNCT07304232
Recruiting
Phase 1

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell NeoplasmAllogeneic Hematopoietic Stem Cell Transplant Recipient
City of Hope Medical Center53 enrolled1 locationNCT04177004
Recruiting
Not Applicable

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Oral MucositisMyeloablative Allogeneic Hematopoietic Cell TransplantationIntraoral Photobiomodulation Therapy+1 more
Dana-Farber Cancer Institute20 enrolled1 locationNCT05335434
Recruiting
Not Applicable

Improve Outcomes for Older Allogeneic Transplant Recipients

Allogeneic Transplantation
Abramson Cancer Center at Penn Medicine72 enrolled1 locationNCT05612789